Asarina Pharma CEO Peter Nordkild: “While we made progress in several areas during Q3 2021, it was frustrating for us that our phase IIa study… Read More »Asarina Pharma AB (publ) Q3 Report 2021 released
Peter Nordkild, VD för Asarina Pharma: "Under tredje kvartalet 2021 gjorde vi framsteg på flera områden men det var frustrerande för oss att vår fas… Read More »Asarina Pharma AB (publ) Rapport om Q3 2021
Asarina Pharma CEO Peter Nordkild: “During the third quarter 2020 we have been firmly focused on execution. We achieved full enrolment for our Phase IIa… Read More »Asarina Pharma AB (publ) Q3 2020 report released
Asarina Pharmas VD Peter Nordkild: ”Under tredje kvartalet 2020 har vi varit mycket fokuserade på leverans. Vi uppnådde full rekrytering i vår fas IIa menstruell… Read More »Asarina Pharma AB (publ) delårsrapport, tredje kvartalet 2020 publicerad
Asarina Pharma, vd Peter Nordkild: ”Under ett intensivt tredje kvartal uppnådde vi ett antal viktiga milstolpar. Vi inkluderade den sista patienten i vår ledande PMDS-studie,… Read More »Asarina Pharma AB (publ) delårsrapport Q3 2019 publicerad
Asarina Pharma CEO Peter Nordkild: “During an intense third quarter we achieved some important milestones. We enrolled the last patient in our landmark PMDD study,… Read More »Asarina Pharma AB (publ) Interim Report Q3 2019 released
Clinical trials on track Stockholm, 14 November, 2018: Asarina Pharma AB releases its Interim Report for 1 July – 30 September, 2018. Third Quarter Highlights… Read More »Interim Report July-September 2018
Kliniska studier i fokus Stockholm, 14 november, 2018: Asarina Pharma AB publicerar sin delårsrapport för perioden 1 juli – 30 september 2018. Viktiga händelser under… Read More »Delårsrapport juli-september 2018